# Profound Medical Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Profound Medical Corp.). ## Overview Profound Medical Corp. develops and commercializes MRI-guided, incision-free therapies for treating diseased tissue, centered on its TULSA-PRO and Sonalleve systems. The company is organized around a holding-company structure with operating subsidiaries and serves hospitals, clinics, and physician-led treatment centers in North America, Europe, and Asia. ## Products & services • TULSA-PRO MRI-guided prostate therapy system • Sonalleve MRI-guided ablation platform • One-time-use devices for each treated patient • Clinical support, Genius services, and patient recruitment • System sales, leases, and service maintenance • Distribution and co-marketing with MRI scanner partners - **TULSA-PRO systems** (45%) — MRI-guided prostate therapy systems used for incision-free ablation procedures. - **Sonalleve systems** (20%) — MRI-guided ablation systems marketed mainly outside North America. - **Disposable devices** (20%) — One-time-use devices consumed per patient treated on installed systems. - **Clinical and service revenue** (15%) — Genius services, procedure support, warranties, and maintenance services. - TULSA-PRO MRI-guided prostate therapy system - Sonalleve MRI-guided ablation platform - One-time-use devices for each treated patient - Clinical support, Genius services, and patient recruitment - System sales, leases, and service maintenance - Distribution and co-marketing with MRI scanner partners ## Customers Profound sells to hospitals, clinics, and other end-users that perform MRI-guided procedures, often through a mix of direct sales and distributor channels. The buying decision is driven by clinical adoption, compatibility with installed MRI scanners, reimbursement support, and the ability to offer less invasive treatment options to patients. - **Hospitals and clinics** (primary) — Buy TULSA-PRO or Sonalleve systems and recurring consumables to perform MRI-guided procedures. - **Physicians and clinicians** (primary) — Influence product adoption, procedure protocols, and ongoing clinical utilization. - **Distributors** (secondary) — Purchase and resell products in markets where Profound lacks direct sales coverage. - **MRI scanner ecosystem partners** (secondary) — Philips, Siemens, and GE-related channels support lead generation and distribution. - Hospitals and clinics purchasing MRI-guided therapy systems - Physicians and clinicians who influence adoption and procedure use - Distributors in markets without a direct commercial presence - MRI scanner ecosystem partners that help generate leads - Centers seeking recurring consumables and procedure support - End-users focused on incision-free, radiation-free treatment options ## Geography Profound has generated revenue in the United States, Europe, and Asia, with the United States using a hybrid recurring model and international markets relying more on capital sales plus recurring consumables. Its systems are compatible with select MRI scanners from Philips, Siemens, and GE Healthcare, which makes geographic expansion dependent on regulatory approvals, local distribution, and installed MRI ecosystems. - United States is a core market for TULSA-PRO commercialization - Europe and Asia are important markets for system sales and consumables - Outside North America, Sonalleve is marketed primarily in Europe and Asia - Direct sales are supplemented by distributors where no local presence exists - Compatibility with Philips, Siemens, and GE MRI scanners shapes market access ## Strategy Profound’s strategy is to expand adoption of TULSA-PRO and Sonalleve by building direct sales capability, supporting clinicians, and increasing utilization of installed systems. It also relies on partnerships with MRI scanner manufacturers and clinical evidence generation to improve reimbursement support and broaden market acceptance. - **Expand TULSA-PRO adoption** (short-term) — Installed-base utilization and procedure volume drive recurring device and service revenue. - **Strengthen reimbursement evidence** (medium-term) — Coverage by government and private payors supports broader clinical adoption. - **Broaden commercial reach through partnerships** (short-term) — MRI ecosystem partners help generate leads and reduce commercialization friction. - **Expand product compatibility and indications** (medium-term) — Wider MRI compatibility and new applications can enlarge the addressable market. - Build direct sales and marketing teams for core products - Increase utilization of installed systems through clinical support - Expand MRI compatibility and reduce design costs - Use clinical trials to support reimbursement coverage - Leverage Philips, Siemens, and GE partnerships for distribution - Pursue additional regulatory approvals in international markets ## Risks Profound depends on physician adoption, reimbursement support, and continued regulatory clearance for its MRI-guided therapies. Its commercialization model also exposes it to supplier concentration, distributor credit risk, and reliance on third-party MRI scanner partners for market access and compatibility. - **Physician and clinician adoption risk** [high] — The systems require clinical acceptance and procedural use to generate recurring revenue. - **Reimbursement and coverage risk** [high] — Coverage by government and private payors affects market uptake and procedure economics. - **Single-source supplier dependence** [high] — Some components are sourced from a single supplier, creating supply and quality risk. - **Distributor credit and collection risk** [medium] — Open-credit sales and international distributor terms can delay or impair cash collection. - **MRI compatibility and partner dependence** [high] — Commercial success depends on compatibility with select MRI scanners and partner promotion. - Adoption depends on clinicians using the systems in practice - Reimbursement coverage may lag clinical evidence generation - Single-source components can disrupt production and raise costs - Distributor sales create collection and credit risk - Commercialization depends on MRI scanner compatibility - Regulatory approvals are needed in new markets ## Accounting Profound’s revenue mix includes capital equipment, one-time-use devices, leases, and service-related revenue, so timing can vary depending on whether a sale is recognized at shipment, installation, or over the service period. Investors should also watch estimates for expected credit losses on distributor receivables, as well as any quarter-to-quarter swings tied to capital sales versus recurring consumables. - **Revenue recognition by product and service type** — Affects quarterly revenue mix and comparability - **Expected credit loss allowance** — Affects receivables and bad debt expense - **Quarterly mix volatility** — Affects reported growth and margin patterns - **Share-based compensation** — Affects SG&A and R&D expense levels - Revenue timing differs between capital sales and recurring consumables - Hybrid U.S. model mixes system, device, and service revenue - Distributor receivables require expected credit loss estimates - Quarterly results can swing with capital equipment shipments - Clinical support and warranty services may be recognized over time --- *Last updated: 2026-04-29T04:49:48.418476+00:00*